The study analysed SARS-CoV-2 Spike S1-specific immunoglobulin G (IgG) antibody response, virus neutralising antibodies and SARS-CoV-2-specific T-cell response after two doses of mRNA COVID-19 vaccine in 800 participants of four different cohorts: 162 participants with chronic kidney disease (CKD) stage 4/5, 159 patients on dialysis, 288 KTRs and 191 controls. The gene discussed is CHMP5; the disease is chronic kidney disease.